Millennium Management
ADCT icon

Millennium Management’s ADC Therapeutics ADCT Stock Holding History

Millennium Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.7M Buy
3,119,154
+2,790,725
+850% +$11M ﹤0.01% 2029
2025
Q4 		$1.16M Sell
328,429
-373,190
-53% -$1.51M ﹤0.01% 4388
2025
Q3 		$2.81M Buy
701,619
+317,945
+83% +$1M ﹤0.01% 3728
2025
Q2 		$1.03M Buy
383,674
+218,857
+133% +$460K ﹤0.01% 4385
2025
Q1 		$232K Sell
164,817
-246,307
-60% -$419K ﹤0.01% 5229
2024
Q4 		$818K Sell
411,124
-301,277
-42% -$788K ﹤0.01% 4364
2024
Q3 		$2.24M Sell
712,401
-104,055
-13% -$328K ﹤0.01% 3600
2024
Q2 		$2.58M Sell
816,456
-193,981
-19% -$771K ﹤0.01% 3308
2024
Q1 		$4.54M Sell
1,010,437
-1,662,373
-62% -$6.13M ﹤0.01% 2957
2023
Q4 		$4.44M Buy
2,672,810
+22,559
+0.9% +$20.8K ﹤0.01% 2893
2023
Q3 		$2.38M Buy
2,650,251
+1,226,102
+86% +$1.63M ﹤0.01% 3394
2023
Q2 		$3.06M Sell
1,424,149
-369,043
-21% -$830K ﹤0.01% 3122
2023
Q1 		$3.5M Sell
1,793,192
-1,607,928
-47% -$5.93M ﹤0.01% 2928
2022
Q4 		$13.1M Buy
3,401,120
+2,980,867
+709% +$11.9M 0.01% 1850
2022
Q3 		$2.03M Buy
420,253
+362,288
+625% +$2.62M ﹤0.01% 3729
2022
Q2 		$461K Buy
+57,965
New +$548K ﹤0.01% 5022
2022
Q1 		– Sell
-40,367
Closed -$815K – 6832
2021
Q4 		$815K Buy
+40,367
New +$973K ﹤0.01% 4606
2021
Q1 		– Sell
-29,679
Closed -$950K – 5842
2020
Q4 		$950K Sell
29,679
-2,068
-7% -$67.8K ﹤0.01% 3778
2020
Q3 		$1.05K Buy
31,747
+16,860
+113% +$730K ﹤0.01% 3098
2020
Q2 		$697K Buy
+14,887
New +$565K ﹤0.01% 3207

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management's ADCT Position: Q1 2026 in Review

Millennium Management increased its ADC Therapeutics (ADCT) stake by 850% in Q1 2026, buying an estimated $11M and bringing the position to 3,119,154 shares worth $11.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2029.

Millennium Management first reported a position in ADCT in Q2 2020 and has held it in 20 quarters since. The position peaked at $13.1M in Q4 2022. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Millennium Management held 3,119,154 shares of ADC Therapeutics worth $11.7M as of Q1 2026.
  • Millennium Management bought 2,790,725 ADC Therapeutics shares in Q1 2026, an estimated $11M.
  • ADC Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2029 holding.
  • Millennium Management first reported a position in ADC Therapeutics in Q2 2020 and has held it in 20 quarters since.
  • Millennium Management's ADC Therapeutics position peaked at $13.1M in Q4 2022.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.